secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001104659-25-028274
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte prices 25M-share public offering at $2.00/share, expects $50M gross proceeds
--------------------------------------------------------------------------------

- Offering of 25,000,000 shares at $2.00/share; gross proceeds ~$50M, net ~$46.6M after discounts and expenses.
- Underwriters have 30-day option to purchase up to an additional 3,750,000 shares at the same price.
- Proceeds to fund SYMVESS commercialization in vascular trauma, pipeline development, and working capital.
- Expected to close on March 27, 2025; TD Cowen, Barclays, and BTIG are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465925028274/0001104659-25-028274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465925028274/tm2510460d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer